Cryoport, Inc. (CYRX) Strategic Agreement and Transaction with DHL Group Call (Transcript)
Cryoport, Inc. (NASDAQ:CYRX ) Strategic Agreement and Transaction with DHL Group Call March 31, 2025 8:30 AM ET Company Participants Todd Fromer - Investor Relations, KCSA Strategic Communications Jerrell Shelton - Chief Executive Officer Tom Heinzen - Vice President, Corporate Development & Investor Relations Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Conference Call Participants Puneet Souda - Leerink Partners Subbu Nambi - Guggenheim Paul Knight - KeyBanc Tejas Savant - Morgan Stanley David Larsen - BTIG David Saxon - Needham Operator Good morning, and welcome to Cryoport's Investor Conference Call. All participants will start in a listen-only mode.
Cryoport, Inc. (CYRX) Q4 2024 Earnings Call Transcript
Start Time: 17:00 January 1, 0000 5:41 PM ET Cryoport, Inc. (NASDAQ:CYRX ) Q4 2024 Earnings Conference Call March 04, 2025, 17:00 PM ET Company Participants Jerrell Shelton - CEO Robert Stefanovich - CFO Mark Sawicki - Chief Scientific Officer Thomas Heinzen - VP IR and Corporate Development Todd Fromer - IR, KCSA Strategic Communications Conference Call Participants Anna Snopkowski - KeyBanc Capital Markets Puneet Souda - Leerink Partners David Saxon - Needham Subbu Nambi - Guggenheim David Larson - BTIG Richard Baldry - Roth Capital Kyle Crews - UBS Matt Stanton - Jefferies Operator Good afternoon, and welcome to Cryoport's Fourth Quarter and Full Year 2024 Earnings Conference Call. All participants will start in a listen-only mode.
CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.51 per share a year ago.
New Strong Buy Stocks for January 29th
MC, LFST, EAT, CYRX and HCP have been added to the Zacks Rank #1 (Strong Buy) List on January 29, 2024.
Cryoport Remains A Disappointing Prospect
Cryoport operates in the promising life sciences sector but continues to suffer from poor fundamentals and significant cash flow challenges. Despite slight revenue growth in Q3 2024, the company remains unprofitable and has seen a drastic share price decline since my initial 'sell' rating. Recent financial improvements are minimal, with net losses narrowing and cash flow turning slightly positive, but the overall outlook remains bleak.
Cryoport, Inc. (CYRX) Q3 2024 Earnings Call Transcript
Cryoport, Inc. (NASDAQ:CYRX ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Todd Fromer - Investor Relations, KCSA Strategic Communications Jerrell Shelton - Chief Executive Officer Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Thomas Heinzen - VP Investor Relations and Corporate Development Conference Call Participants Paul Knight - KeyBanc David Larsen - BTIG Puneet Souda - Leerink Partners Operator Good afternoon and welcome to the Cryoport Second Quarter 2024 Earnings Call. All participants will start in a listen-only mode.
CryoPort, Inc. (CYRX) Reports Q3 Loss, Misses Revenue Estimates
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.31 per share a year ago.
CryoPort, Inc. (CYRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
CryoPort (CYRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Schall Law Firm Is Inquiring Into Possible Securities Fraud By Cryoport Inc And Shareholders Are Encouraged To Reach Out
LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Looking Into Cryoport Inc For Possible Securities Law Violations And Encourages Shareholders To Help
LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Inquiring Into Potential Securities Law Violations By Cryoport Inc And Asks Investors To Help
LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Begins Investigation Into Cryoport Inc And Asks Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
